Whole bladder wall photodynamic therapy with in situ light dosimetry for carcinoma in situ of the bladder.
We report on the preliminary results of 12 patients with multifocal carcinoma in situ of the bladder treated with whole bladder wall photodynamic therapy. The total light dose (scattered plus nonscattered light) measured in situ was 100 joules per cm.2 in the first 6 patients (group 1) and 75 joules per cm.2 in the remaining 6 (group 2). These light doses correspond on the average to 27 joules per cm.2 and 15.5 joules per cm.2 nonscattered light as reported by other investigators. Followup ranged from 6 to 22 months (average 11.5). In group 1, 2 tumors recurred after 6 and 9 months, respectively, and 2 other patients had a permanently shrunken bladder without evidence of disease. In group 2, 1 tumor recurred 5 months after photodynamic therapy. In this group the bladder capacity increased on the average to 135% of the pretreatment value 3 months after photodynamic therapy. All recurrences were in patients with a history of invasive bladder cancer (stages T1 and T2). These preliminary results demonstrate the importance of in situ scattered light dosimetry for minimizing local side effects of whole bladder photodynamic therapy.
D'Hallewin
M A
MA
Department of Urology, University Clinic Sint-Pieter, Catholic University of Leuven, Belgium.
Baert
L
L
Marijnissen
J P
JP
Star
W M
WM
D000368:Aged; D002278:Carcinoma in Situ / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008027:Light; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000295:instrumentation / Q000379:methods; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*